#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=2 .
1-1	0-1	2	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Materials and Methods
2-1	4-13	Materials	substance	new	_	_
2-2	14-17	and	_	_	_	_
2-3	18-25	Methods	abstract	new	coref	11-108

#Text=This study was designed and developed according to the preferred reporting items for systematic reviews and meta-analysis ( PRISMA ) guidelines , an evidence-based set of minimum items for assessing the benefits and harms of a given healthcare intervention .
3-1	26-30	This	abstract[4]	new[4]	coref	17-16[126_4]
3-2	31-36	study	abstract[4]	new[4]	_	_
3-3	37-40	was	_	_	_	_
3-4	41-49	designed	_	_	_	_
3-5	50-53	and	_	_	_	_
3-6	54-63	developed	_	_	_	_
3-7	64-73	according	_	_	_	_
3-8	74-76	to	_	_	_	_
3-9	77-80	the	object[6]	new[6]	_	_
3-10	81-90	preferred	object[6]	new[6]	_	_
3-11	91-100	reporting	abstract|object[6]	new|new[6]	_	_
3-12	101-106	items	object[6]	new[6]	_	_
3-13	107-110	for	object[6]	new[6]	_	_
3-14	111-121	systematic	object[6]|abstract[7]	new[6]|new[7]	_	_
3-15	122-129	reviews	object[6]|abstract[7]	new[6]|new[7]	_	_
3-16	130-133	and	object[6]	new[6]	_	_
3-17	134-147	meta-analysis	object[6]|abstract	new[6]|new	appos	3-19
3-18	148-149	(	object[6]	new[6]	_	_
3-19	150-156	PRISMA	object[6]|abstract	new[6]|giv	_	_
3-20	157-158	)	object[6]	new[6]	_	_
3-21	159-169	guidelines	object[6]|abstract	new[6]|new	coref	21-15[157_0]
3-22	170-171	,	object[6]	new[6]	_	_
3-23	172-174	an	object[6]|abstract[11]	new[6]|new[11]	_	_
3-24	175-189	evidence-based	object[6]|abstract[11]	new[6]|new[11]	_	_
3-25	190-193	set	object[6]|abstract[11]	new[6]|new[11]	_	_
3-26	194-196	of	object[6]|abstract[11]	new[6]|new[11]	_	_
3-27	197-204	minimum	object[6]|abstract[11]|object[12]	new[6]|new[11]|new[12]	_	_
3-28	205-210	items	object[6]|abstract[11]|object[12]	new[6]|new[11]|new[12]	_	_
3-29	211-214	for	_	_	_	_
3-30	215-224	assessing	_	_	_	_
3-31	225-228	the	abstract[13]	new[13]	_	_
3-32	229-237	benefits	abstract[13]	new[13]	_	_
3-33	238-241	and	_	_	_	_
3-34	242-247	harms	abstract[14]	new[14]	_	_
3-35	248-250	of	abstract[14]	new[14]	_	_
3-36	251-252	a	abstract[14]|event[16]	new[14]|new[16]	coref	11-120[86_16]
3-37	253-258	given	abstract[14]|event[16]	new[14]|new[16]	_	_
3-38	259-269	healthcare	abstract[14]|organization|event[16]	new[14]|new|new[16]	_	_
3-39	270-282	intervention	abstract[14]|event[16]	new[14]|new[16]	_	_
3-40	283-284	.	_	_	_	_

#Text=2.1 .
4-1	285-288	2.1	abstract	new	_	_
4-2	289-290	.	_	_	_	_

#Text=Literature Search
5-1	291-301	Literature	abstract|abstract[19]	new|new[19]	coref|coref|coref|coref	6-3[21_0]|15-7[104_19]|6-3[21_0]|15-7[104_19]
5-2	302-308	Search	abstract[19]	new[19]	_	_

#Text=We searched the literature in various electronic bibliographic databases ( PubMed/Medline , Embase , EBSCO , Cochrane databases , Lilacs , and Dialnet ) for all entries up until 30 March 2019 , without applying any publication age limitations .
6-1	309-311	We	person	acc	ana	11-3
6-2	312-320	searched	_	_	_	_
6-3	321-324	the	abstract[21]	giv[21]	coref	15-8[0_21]
6-4	325-335	literature	abstract[21]	giv[21]	_	_
6-5	336-338	in	_	_	_	_
6-6	339-346	various	object[22]	new[22]	coref	6-17[27_22]
6-7	347-357	electronic	object[22]	new[22]	_	_
6-8	358-371	bibliographic	object[22]	new[22]	_	_
6-9	372-381	databases	object[22]	new[22]	_	_
6-10	382-383	(	_	_	_	_
6-11	384-398	PubMed/Medline	organization	new	_	_
6-12	399-400	,	_	_	_	_
6-13	401-407	Embase	organization	new	_	_
6-14	408-409	,	_	_	_	_
6-15	410-415	EBSCO	organization	new	_	_
6-16	416-417	,	_	_	_	_
6-17	418-426	Cochrane	organization|object[27]	new|giv[27]	coref|coref|coref|coref	8-7[43_27]|21-16|8-7[43_27]|21-16
6-18	427-436	databases	object[27]	giv[27]	_	_
6-19	437-438	,	_	_	_	_
6-20	439-445	Lilacs	organization	new	_	_
6-21	446-447	,	_	_	_	_
6-22	448-451	and	_	_	_	_
6-23	452-459	Dialnet	organization	new	_	_
6-24	460-461	)	_	_	_	_
6-25	462-465	for	_	_	_	_
6-26	466-469	all	place[30]	new[30]	_	_
6-27	470-477	entries	place[30]	new[30]	_	_
6-28	478-480	up	place[30]	new[30]	_	_
6-29	481-486	until	place[30]	new[30]	_	_
6-30	487-489	30	place[30]|time[31]	new[30]|new[31]	_	_
6-31	490-495	March	place[30]|time[31]|time[32]	new[30]|new[31]|new[32]	_	_
6-32	496-500	2019	place[30]|time[31]|time[32]|time	new[30]|new[31]|new[32]|new	_	_
6-33	501-502	,	_	_	_	_
6-34	503-510	without	_	_	_	_
6-35	511-519	applying	_	_	_	_
6-36	520-523	any	abstract[36]	new[36]	_	_
6-37	524-535	publication	abstract|abstract[36]	new|new[36]	_	_
6-38	536-539	age	abstract|abstract[36]	new|new[36]	coref	17-25[129_0]
6-39	540-551	limitations	abstract[36]	new[36]	_	_
6-40	552-553	.	_	_	_	_

#Text=The reference lists of all the relevant articles were manually cross-referenced in order to identify any additional articles .
7-1	554-557	The	object[38]	new[38]	_	_
7-2	558-567	reference	abstract|object[38]	new|new[38]	_	_
7-3	568-573	lists	object[38]	new[38]	_	_
7-4	574-576	of	object[38]	new[38]	_	_
7-5	577-580	all	object[38]|abstract[39]	new[38]|new[39]	coref	7-16[40_39]
7-6	581-584	the	object[38]|abstract[39]	new[38]|new[39]	_	_
7-7	585-593	relevant	object[38]|abstract[39]	new[38]|new[39]	_	_
7-8	594-602	articles	object[38]|abstract[39]	new[38]|new[39]	_	_
7-9	603-607	were	_	_	_	_
7-10	608-616	manually	_	_	_	_
7-11	617-633	cross-referenced	_	_	_	_
7-12	634-636	in	_	_	_	_
7-13	637-642	order	_	_	_	_
7-14	643-645	to	_	_	_	_
7-15	646-654	identify	_	_	_	_
7-16	655-658	any	abstract[40]	giv[40]	coref	16-24[115_40]
7-17	659-669	additional	abstract[40]	giv[40]	_	_
7-18	670-678	articles	abstract[40]	giv[40]	_	_
7-19	679-680	.	_	_	_	_

#Text=The primary search terms used for all six databases were ‘ leucine ’ and ‘ sarcopenia ’ , as well as one of the following terms : ‘ older ’ , ‘ elderly ’ , ‘ disease ’ or ‘ trial ’ .
8-1	681-684	The	abstract[42]	new[42]	coref	8-24[47_42]
8-2	685-692	primary	abstract[42]	new[42]	_	_
8-3	693-699	search	event|abstract[42]	new|new[42]	_	_
8-4	700-705	terms	abstract[42]	new[42]	_	_
8-5	706-710	used	_	_	_	_
8-6	711-714	for	_	_	_	_
8-7	715-718	all	object[43]	giv[43]	_	_
8-8	719-722	six	object[43]	giv[43]	_	_
8-9	723-732	databases	object[43]	giv[43]	_	_
8-10	733-737	were	_	_	_	_
8-11	738-739	‘	abstract[44]	new[44]	coref	11-117[0_44]
8-12	740-747	leucine	abstract[44]	new[44]	_	_
8-13	748-749	’	abstract[44]	new[44]	_	_
8-14	750-753	and	abstract[44]	new[44]	_	_
8-15	754-755	‘	abstract[44]|abstract[45]	new[44]|new[45]	coref	11-80[0_45]
8-16	756-766	sarcopenia	abstract[44]|abstract[45]	new[44]|new[45]	_	_
8-17	767-768	’	abstract[44]|abstract[45]	new[44]|new[45]	_	_
8-18	769-770	,	abstract[44]	new[44]	_	_
8-19	771-773	as	abstract[44]	new[44]	_	_
8-20	774-778	well	abstract[44]	new[44]	_	_
8-21	779-781	as	abstract[44]	new[44]	_	_
8-22	782-785	one	abstract[44]|abstract[46]	new[44]|new[46]	_	_
8-23	786-788	of	abstract[44]|abstract[46]	new[44]|new[46]	_	_
8-24	789-792	the	abstract[44]|abstract[46]|abstract[47]	new[44]|new[46]|giv[47]	appos	8-32[49_47]
8-25	793-802	following	abstract[44]|abstract[46]|abstract[47]	new[44]|new[46]|giv[47]	_	_
8-26	803-808	terms	abstract[44]|abstract[46]|abstract[47]	new[44]|new[46]|giv[47]	_	_
8-27	809-810	:	_	_	_	_
8-28	811-812	‘	_	_	_	_
8-29	813-818	older	_	_	_	_
8-30	819-820	’	_	_	_	_
8-31	821-822	,	_	_	_	_
8-32	823-824	‘	abstract[49]	giv[49]	_	_
8-33	825-832	elderly	abstract[49]	giv[49]	_	_
8-34	833-834	’	abstract[49]	giv[49]	_	_
8-35	835-836	,	abstract[49]	giv[49]	_	_
8-36	837-838	‘	abstract[48]|abstract[49]	new[48]|giv[49]	_	_
8-37	839-846	disease	abstract[48]|abstract[49]	new[48]|giv[49]	_	_
8-38	847-848	’	abstract[48]|abstract[49]	new[48]|giv[49]	_	_
8-39	849-851	or	abstract[49]	giv[49]	_	_
8-40	852-853	‘	abstract[49]	giv[49]	_	_
8-41	854-859	trial	abstract[49]	giv[49]	_	_
8-42	860-861	’	abstract[49]	giv[49]	_	_
8-43	862-863	.	_	_	_	_

#Text=2.2 .
9-1	864-867	2.2	abstract	new	_	_
9-2	868-869	.	_	_	_	_

#Text=Inclusion and Exclusion Criteria
10-1	870-879	Inclusion	person|abstract[52]	new|new[52]	coref|coref|coref|coref	11-11|16-34[119_52]|11-11|16-34[119_52]
10-2	880-883	and	abstract[52]	new[52]	_	_
10-3	884-893	Exclusion	abstract[52]|abstract|abstract[54]	new[52]|new|new[54]	coref|coref	11-9[60_54]|11-9[60_54]
10-4	894-902	Criteria	abstract[52]|abstract[54]	new[52]|new[54]	_	_

#Text=To answer our research questions , we applied the following inclusion criteria to each of the considered manuscripts : ( 1 ) It was acknowledged as an original article ; we included experimental studies ( randomised and placebo-controlled trials ) and observational studies ( cohort , cross-sectional , and case-control studies ) ; ( 2 ) it was a full text published either in English , Portuguese , or Spanish ; ( 3 ) at least one of the sarcopenia criteria was measured : Muscular mass and/or muscular strength and/or physical performance ; ( 4 ) a description of how sarcopenia was evaluated was defined in the methods section ; ( 5 ) the concentration of leucine used in the intervention was specified or could be calculated .
11-1	903-905	To	_	_	_	_
11-2	906-912	answer	_	_	_	_
11-3	913-916	our	person|abstract[57]	giv|new[57]	ana|ana	11-7|11-7
11-4	917-925	research	abstract|abstract[57]	new|new[57]	_	_
11-5	926-935	questions	abstract[57]	new[57]	_	_
11-6	936-937	,	_	_	_	_
11-7	938-940	we	person	giv	ana	11-31
11-8	941-948	applied	_	_	_	_
11-9	949-952	the	abstract[60]	giv[60]	coref	11-79[76_60]
11-10	953-962	following	abstract[60]	giv[60]	_	_
11-11	963-972	inclusion	person|abstract[60]	giv|giv[60]	ana	11-23
11-12	973-981	criteria	abstract[60]	giv[60]	_	_
11-13	982-984	to	abstract[60]	giv[60]	_	_
11-14	985-989	each	abstract[60]	giv[60]	_	_
11-15	990-992	of	abstract[60]	giv[60]	_	_
11-16	993-996	the	abstract[60]|object[61]	giv[60]|new[61]	coref	15-3[102_61]
11-17	997-1007	considered	abstract[60]|object[61]	giv[60]|new[61]	_	_
11-18	1008-1019	manuscripts	abstract[60]|object[61]	giv[60]|new[61]	_	_
11-19	1020-1021	:	_	_	_	_
11-20	1022-1023	(	_	_	_	_
11-21	1024-1025	1	_	_	_	_
11-22	1026-1027	)	_	_	_	_
11-23	1028-1030	It	person	giv	ana	11-57
11-24	1031-1034	was	_	_	_	_
11-25	1035-1047	acknowledged	_	_	_	_
11-26	1048-1050	as	_	_	_	_
11-27	1051-1053	an	_	_	_	_
11-28	1054-1062	original	_	_	_	_
11-29	1063-1070	article	_	_	_	_
11-30	1071-1072	;	_	_	_	_
11-31	1073-1075	we	person	giv	ana	16-34
11-32	1076-1084	included	_	_	_	_
11-33	1085-1097	experimental	event[64]	new[64]	_	_
11-34	1098-1105	studies	event[64]	new[64]	_	_
11-35	1106-1107	(	_	_	_	_
11-36	1108-1118	randomised	_	_	_	_
11-37	1119-1122	and	_	_	_	_
11-38	1123-1141	placebo-controlled	_	_	_	_
11-39	1142-1148	trials	abstract	new	_	_
11-40	1149-1150	)	_	_	_	_
11-41	1151-1154	and	_	_	_	_
11-42	1155-1168	observational	event[66]	new[66]	coref	11-50[68_66]
11-43	1169-1176	studies	event[66]	new[66]	_	_
11-44	1177-1178	(	_	_	_	_
11-45	1179-1185	cohort	abstract	new	_	_
11-46	1186-1187	,	_	_	_	_
11-47	1188-1203	cross-sectional	_	_	_	_
11-48	1204-1205	,	_	_	_	_
11-49	1206-1209	and	_	_	_	_
11-50	1210-1222	case-control	event[68]	giv[68]	coref	12-1[0_68]
11-51	1223-1230	studies	event[68]	giv[68]	_	_
11-52	1231-1232	)	event[68]	giv[68]	_	_
11-53	1233-1234	;	event[68]	giv[68]	_	_
11-54	1235-1236	(	event[68]	giv[68]	_	_
11-55	1237-1238	2	event[68]	giv[68]	_	_
11-56	1239-1240	)	event[68]	giv[68]	_	_
11-57	1241-1243	it	person	giv	coref	11-59[70_0]
11-58	1244-1247	was	_	_	_	_
11-59	1248-1249	a	person[70]	giv[70]	coref	16-34[118_70]
11-60	1250-1254	full	person[70]	giv[70]	_	_
11-61	1255-1259	text	person[70]	giv[70]	_	_
11-62	1260-1269	published	_	_	_	_
11-63	1270-1276	either	abstract[71]	new[71]	_	_
11-64	1277-1279	in	abstract[71]	new[71]	_	_
11-65	1280-1287	English	abstract[71]	new[71]	_	_
11-66	1288-1289	,	_	_	_	_
11-67	1290-1300	Portuguese	abstract	new	_	_
11-68	1301-1302	,	_	_	_	_
11-69	1303-1305	or	_	_	_	_
11-70	1306-1313	Spanish	abstract[73]	new[73]	_	_
11-71	1314-1315	;	abstract[73]	new[73]	_	_
11-72	1316-1317	(	abstract[73]	new[73]	_	_
11-73	1318-1319	3	abstract[73]	new[73]	_	_
11-74	1320-1321	)	abstract[73]	new[73]	_	_
11-75	1322-1324	at	abstract[74]	new[74]	_	_
11-76	1325-1330	least	abstract[74]	new[74]	_	_
11-77	1331-1334	one	abstract[74]	new[74]	_	_
11-78	1335-1337	of	abstract[74]	new[74]	_	_
11-79	1338-1341	the	abstract[74]|abstract[76]	new[74]|giv[76]	coref	16-37[121_76]
11-80	1342-1352	sarcopenia	abstract[74]|abstract|abstract[76]	new[74]|giv|giv[76]	coref	11-101
11-81	1353-1361	criteria	abstract[74]|abstract[76]	new[74]|giv[76]	_	_
11-82	1362-1365	was	_	_	_	_
11-83	1366-1374	measured	_	_	_	_
11-84	1375-1376	:	_	_	_	_
11-85	1377-1385	Muscular	abstract[77]	new[77]	_	_
11-86	1386-1390	mass	abstract[77]	new[77]	_	_
11-87	1391-1397	and/or	_	_	_	_
11-88	1398-1406	muscular	abstract[78]	new[78]	_	_
11-89	1407-1415	strength	abstract[78]	new[78]	_	_
11-90	1416-1422	and/or	abstract[78]	new[78]	_	_
11-91	1423-1431	physical	abstract[78]|abstract[79]	new[78]|new[79]	coref	21-38[0_79]
11-92	1432-1443	performance	abstract[78]|abstract[79]	new[78]|new[79]	_	_
11-93	1444-1445	;	_	_	_	_
11-94	1446-1447	(	_	_	_	_
11-95	1448-1449	4	_	_	_	_
11-96	1450-1451	)	_	_	_	_
11-97	1452-1453	a	abstract[80]	new[80]	_	_
11-98	1454-1465	description	abstract[80]	new[80]	_	_
11-99	1466-1468	of	abstract[80]	new[80]	_	_
11-100	1469-1472	how	abstract[80]	new[80]	_	_
11-101	1473-1483	sarcopenia	abstract	giv	coref	17-50
11-102	1484-1487	was	_	_	_	_
11-103	1488-1497	evaluated	_	_	_	_
11-104	1498-1501	was	_	_	_	_
11-105	1502-1509	defined	_	_	_	_
11-106	1510-1512	in	_	_	_	_
11-107	1513-1516	the	abstract[83]	new[83]	_	_
11-108	1517-1524	methods	abstract|abstract[83]	giv|new[83]	coref	17-50[139_0]
11-109	1525-1532	section	abstract[83]	new[83]	_	_
11-110	1533-1534	;	_	_	_	_
11-111	1535-1536	(	_	_	_	_
11-112	1537-1538	5	_	_	_	_
11-113	1539-1540	)	_	_	_	_
11-114	1541-1544	the	quantity[84]	new[84]	_	_
11-115	1545-1558	concentration	quantity[84]	new[84]	_	_
11-116	1559-1561	of	quantity[84]	new[84]	_	_
11-117	1562-1569	leucine	quantity[84]|abstract	new[84]|giv	coref	17-42
11-118	1570-1574	used	_	_	_	_
11-119	1575-1577	in	_	_	_	_
11-120	1578-1581	the	event[86]	giv[86]	_	_
11-121	1582-1594	intervention	event[86]	giv[86]	_	_
11-122	1595-1598	was	_	_	_	_
11-123	1599-1608	specified	_	_	_	_
11-124	1609-1611	or	_	_	_	_
11-125	1612-1617	could	_	_	_	_
11-126	1618-1620	be	_	_	_	_
11-127	1621-1631	calculated	_	_	_	_
11-128	1632-1633	.	_	_	_	_

#Text=Studies performed in animals , case-report studies , letters to the Editor , abstracts from conferences , books , PhD theses were excluded .
12-1	1634-1641	Studies	event	giv	coref	12-6[89_0]
12-2	1642-1651	performed	_	_	_	_
12-3	1652-1654	in	_	_	_	_
12-4	1655-1662	animals	animal	new	_	_
12-5	1663-1664	,	_	_	_	_
12-6	1665-1676	case-report	event[89]	giv[89]	coref	16-6[0_89]
12-7	1677-1684	studies	event[89]	giv[89]	_	_
12-8	1685-1686	,	_	_	_	_
12-9	1687-1694	letters	abstract[90]	new[90]	_	_
12-10	1695-1697	to	abstract[90]	new[90]	_	_
12-11	1698-1701	the	abstract[90]|person[91]	new[90]|new[91]	_	_
12-12	1702-1708	Editor	abstract[90]|person[91]	new[90]|new[91]	_	_
12-13	1709-1710	,	abstract[90]	new[90]	_	_
12-14	1711-1720	abstracts	abstract[90]|abstract[92]	new[90]|new[92]	coref	16-22[114_92]
12-15	1721-1725	from	abstract[90]|abstract[92]	new[90]|new[92]	_	_
12-16	1726-1737	conferences	abstract[90]|abstract[92]|event	new[90]|new[92]|new	_	_
12-17	1738-1739	,	abstract[90]|abstract[92]	new[90]|new[92]	_	_
12-18	1740-1745	books	abstract[90]|abstract[92]|object	new[90]|new[92]|new	_	_
12-19	1746-1747	,	abstract[90]|abstract[92]	new[90]|new[92]	_	_
12-20	1748-1751	PhD	abstract[90]|abstract[92]|abstract|object[96]	new[90]|new[92]|new|new[96]	_	_
12-21	1752-1758	theses	abstract[90]|abstract[92]|object[96]	new[90]|new[92]|new[96]	_	_
12-22	1759-1763	were	_	_	_	_
12-23	1764-1772	excluded	_	_	_	_
12-24	1773-1774	.	_	_	_	_

#Text=2.3 .
13-1	1775-1778	2.3	abstract	new	_	_
13-2	1779-1780	.	_	_	_	_

#Text=Data Collection and Analysis
14-1	1781-1785	Data	abstract|abstract[99]	new|new[99]	_	_
14-2	1786-1796	Collection	abstract[99]	new[99]	_	_
14-3	1797-1800	and	_	_	_	_
14-4	1801-1809	Analysis	abstract	new	_	_

#Text=Details of the manuscripts identified in the literature search were uploaded into a web-based system , which was used to manage the screening process and remove any duplicate citations .
15-1	1810-1817	Details	object[101]	new[101]	_	_
15-2	1818-1820	of	object[101]	new[101]	_	_
15-3	1821-1824	the	object[101]|object[102]	new[101]|giv[102]	_	_
15-4	1825-1836	manuscripts	object[101]|object[102]	new[101]|giv[102]	_	_
15-5	1837-1847	identified	_	_	_	_
15-6	1848-1850	in	_	_	_	_
15-7	1851-1854	the	abstract[104]	giv[104]	_	_
15-8	1855-1865	literature	abstract|abstract[104]	giv|giv[104]	_	_
15-9	1866-1872	search	abstract[104]	giv[104]	_	_
15-10	1873-1877	were	_	_	_	_
15-11	1878-1886	uploaded	_	_	_	_
15-12	1887-1891	into	_	_	_	_
15-13	1892-1893	a	abstract[105]	new[105]	_	_
15-14	1894-1903	web-based	abstract[105]	new[105]	_	_
15-15	1904-1910	system	abstract[105]	new[105]	_	_
15-16	1911-1912	,	_	_	_	_
15-17	1913-1918	which	_	_	_	_
15-18	1919-1922	was	_	_	_	_
15-19	1923-1927	used	_	_	_	_
15-20	1928-1930	to	_	_	_	_
15-21	1931-1937	manage	_	_	_	_
15-22	1938-1941	the	event[107]	new[107]	_	_
15-23	1942-1951	screening	abstract|event[107]	new|new[107]	_	_
15-24	1952-1959	process	event[107]	new[107]	_	_
15-25	1960-1963	and	_	_	_	_
15-26	1964-1970	remove	_	_	_	_
15-27	1971-1974	any	abstract[108]	new[108]	_	_
15-28	1975-1984	duplicate	abstract[108]	new[108]	_	_
15-29	1985-1994	citations	abstract[108]	new[108]	_	_
15-30	1995-1996	.	_	_	_	_

#Text=In order to determine which studies would be included , three members of the review team independently screened the titles and abstracts of these articles and the full texts were retrieved based on our inclusion and exclusion criteria .
16-1	1997-1999	In	_	_	_	_
16-2	2000-2005	order	_	_	_	_
16-3	2006-2008	to	_	_	_	_
16-4	2009-2018	determine	_	_	_	_
16-5	2019-2024	which	_	_	_	_
16-6	2025-2032	studies	event	giv	_	_
16-7	2033-2038	would	_	_	_	_
16-8	2039-2041	be	_	_	_	_
16-9	2042-2050	included	_	_	_	_
16-10	2051-2052	,	_	_	_	_
16-11	2053-2058	three	person[110]	new[110]	_	_
16-12	2059-2066	members	person[110]	new[110]	_	_
16-13	2067-2069	of	person[110]	new[110]	_	_
16-14	2070-2073	the	person[110]|organization[112]	new[110]|new[112]	_	_
16-15	2074-2080	review	person[110]|event|organization[112]	new[110]|new|new[112]	_	_
16-16	2081-2085	team	person[110]|organization[112]	new[110]|new[112]	_	_
16-17	2086-2099	independently	_	_	_	_
16-18	2100-2108	screened	_	_	_	_
16-19	2109-2112	the	abstract[113]	new[113]	_	_
16-20	2113-2119	titles	abstract[113]	new[113]	_	_
16-21	2120-2123	and	_	_	_	_
16-22	2124-2133	abstracts	abstract[114]	giv[114]	_	_
16-23	2134-2136	of	abstract[114]	giv[114]	_	_
16-24	2137-2142	these	abstract[114]|abstract[115]	giv[114]|giv[115]	_	_
16-25	2143-2151	articles	abstract[114]|abstract[115]	giv[114]|giv[115]	_	_
16-26	2152-2155	and	_	_	_	_
16-27	2156-2159	the	object[116]	new[116]	_	_
16-28	2160-2164	full	object[116]	new[116]	_	_
16-29	2165-2170	texts	object[116]	new[116]	_	_
16-30	2171-2175	were	_	_	_	_
16-31	2176-2185	retrieved	_	_	_	_
16-32	2186-2191	based	_	_	_	_
16-33	2192-2194	on	_	_	_	_
16-34	2195-2198	our	person|person[118]|abstract[119]	giv|giv[118]|giv[119]	coref|ana|coref|ana|coref|ana	17-33[0_118]|21-1|17-33[0_118]|21-1|17-33[0_118]|21-1
16-35	2199-2208	inclusion	person[118]|abstract[119]	giv[118]|giv[119]	_	_
16-36	2209-2212	and	abstract[119]	giv[119]	_	_
16-37	2213-2222	exclusion	abstract[119]|person|abstract[121]	giv[119]|new|giv[121]	_	_
16-38	2223-2231	criteria	abstract[119]|abstract[121]	giv[119]|giv[121]	_	_
16-39	2232-2233	.	_	_	_	_

#Text=Two reviewers independently extracted the following data from each article : The country in which the study was conducted , number of participants , age of the participants at the time of inclusion , sex of the participants , amount of leucine administered , co-administration of other substances , sarcopenia evaluation methods , and the main and secondary outcomes of the study .
17-1	2234-2237	Two	person[122]	new[122]	coref	18-4[143_122]
17-2	2238-2247	reviewers	person[122]	new[122]	_	_
17-3	2248-2261	independently	_	_	_	_
17-4	2262-2271	extracted	_	_	_	_
17-5	2272-2275	the	abstract[123]	new[123]	coref	18-10[0_123]
17-6	2276-2285	following	abstract[123]	new[123]	_	_
17-7	2286-2290	data	abstract[123]	new[123]	_	_
17-8	2291-2295	from	abstract[123]	new[123]	_	_
17-9	2296-2300	each	abstract[123]|object[124]	new[123]|new[124]	_	_
17-10	2301-2308	article	abstract[123]|object[124]	new[123]|new[124]	_	_
17-11	2309-2310	:	_	_	_	_
17-12	2311-2314	The	place[125]	new[125]	_	_
17-13	2315-2322	country	place[125]	new[125]	_	_
17-14	2323-2325	in	_	_	_	_
17-15	2326-2331	which	_	_	_	_
17-16	2332-2335	the	abstract[126]	giv[126]	coref	17-61[141_126]
17-17	2336-2341	study	abstract[126]	giv[126]	_	_
17-18	2342-2345	was	_	_	_	_
17-19	2346-2355	conducted	_	_	_	_
17-20	2356-2357	,	_	_	_	_
17-21	2358-2364	number	abstract[127]	new[127]	_	_
17-22	2365-2367	of	abstract[127]	new[127]	_	_
17-23	2368-2380	participants	abstract[127]|person	new[127]|new	coref	17-27[130_0]
17-24	2381-2382	,	_	_	_	_
17-25	2383-2386	age	abstract[129]	giv[129]	_	_
17-26	2387-2389	of	abstract[129]	giv[129]	_	_
17-27	2390-2393	the	abstract[129]|person[130]	giv[129]|giv[130]	coref	21-43[165_130]
17-28	2394-2406	participants	abstract[129]|person[130]	giv[129]|giv[130]	_	_
17-29	2407-2409	at	abstract[129]|person[130]	giv[129]|giv[130]	_	_
17-30	2410-2413	the	abstract[129]|person[130]	giv[129]|giv[130]	_	_
17-31	2414-2418	time	abstract[129]|person[130]	giv[129]|giv[130]	_	_
17-32	2419-2421	of	abstract[129]|person[130]	giv[129]|giv[130]	_	_
17-33	2422-2431	inclusion	abstract[129]|person[130]|person	giv[129]|giv[130]|giv	_	_
17-34	2432-2433	,	abstract[129]|person[130]	giv[129]|giv[130]	_	_
17-35	2434-2437	sex	abstract[129]|person[130]|abstract[132]	giv[129]|giv[130]|new[132]	_	_
17-36	2438-2440	of	abstract[129]|person[130]|abstract[132]	giv[129]|giv[130]|new[132]	_	_
17-37	2441-2444	the	abstract[129]|person[130]|abstract[132]	giv[129]|giv[130]|new[132]	_	_
17-38	2445-2457	participants	abstract[129]|person[130]|abstract[132]	giv[129]|giv[130]|new[132]	_	_
17-39	2458-2459	,	abstract[129]|person[130]	giv[129]|giv[130]	_	_
17-40	2460-2466	amount	abstract[129]|person[130]|quantity[133]	giv[129]|giv[130]|new[133]	_	_
17-41	2467-2469	of	abstract[129]|person[130]|quantity[133]	giv[129]|giv[130]|new[133]	_	_
17-42	2470-2477	leucine	abstract[129]|person[130]|quantity[133]|abstract	giv[129]|giv[130]|new[133]|giv	_	_
17-43	2478-2490	administered	abstract[129]|person[130]	giv[129]|giv[130]	_	_
17-44	2491-2492	,	abstract[129]|person[130]	giv[129]|giv[130]	_	_
17-45	2493-2510	co-administration	abstract[129]|person[130]|abstract[135]	giv[129]|giv[130]|new[135]	_	_
17-46	2511-2513	of	abstract[129]|person[130]|abstract[135]	giv[129]|giv[130]|new[135]	_	_
17-47	2514-2519	other	abstract[129]|person[130]|abstract[135]|substance[136]	giv[129]|giv[130]|new[135]|new[136]	_	_
17-48	2520-2530	substances	abstract[129]|person[130]|abstract[135]|substance[136]	giv[129]|giv[130]|new[135]|new[136]	_	_
17-49	2531-2532	,	abstract[129]|person[130]|abstract[135]	giv[129]|giv[130]|new[135]	_	_
17-50	2533-2543	sarcopenia	abstract[129]|person[130]|abstract[135]|abstract|abstract[139]	giv[129]|giv[130]|new[135]|giv|giv[139]	_	_
17-51	2544-2554	evaluation	abstract[129]|person[130]|abstract[135]|abstract|abstract[139]	giv[129]|giv[130]|new[135]|new|giv[139]	_	_
17-52	2555-2562	methods	abstract[129]|person[130]|abstract[135]|abstract[139]	giv[129]|giv[130]|new[135]|giv[139]	_	_
17-53	2563-2564	,	abstract[129]|person[130]|abstract[135]	giv[129]|giv[130]|new[135]	_	_
17-54	2565-2568	and	abstract[129]|person[130]|abstract[135]	giv[129]|giv[130]|new[135]	_	_
17-55	2569-2572	the	abstract[129]|person[130]|abstract[135]|abstract[140]	giv[129]|giv[130]|new[135]|new[140]	_	_
17-56	2573-2577	main	abstract[129]|person[130]|abstract[135]|abstract[140]	giv[129]|giv[130]|new[135]|new[140]	_	_
17-57	2578-2581	and	abstract[129]|person[130]|abstract[135]|abstract[140]	giv[129]|giv[130]|new[135]|new[140]	_	_
17-58	2582-2591	secondary	abstract[129]|person[130]|abstract[135]|abstract[140]	giv[129]|giv[130]|new[135]|new[140]	_	_
17-59	2592-2600	outcomes	abstract[129]|person[130]|abstract[135]|abstract[140]	giv[129]|giv[130]|new[135]|new[140]	_	_
17-60	2601-2603	of	abstract[129]|person[130]|abstract[135]|abstract[140]	giv[129]|giv[130]|new[135]|new[140]	_	_
17-61	2604-2607	the	abstract[129]|person[130]|abstract[135]|abstract[140]|abstract[141]	giv[129]|giv[130]|new[135]|new[140]|giv[141]	coref	21-8[154_141]
17-62	2608-2613	study	abstract[129]|person[130]|abstract[135]|abstract[140]|abstract[141]	giv[129]|giv[130]|new[135]|new[140]|giv[141]	_	_
17-63	2614-2615	.	_	_	_	_

#Text=Any disagreement between the reviewers regarding the papers and data extracted from them was resolved by the third author .
18-1	2616-2619	Any	abstract[142]	new[142]	_	_
18-2	2620-2632	disagreement	abstract[142]	new[142]	_	_
18-3	2633-2640	between	abstract[142]	new[142]	_	_
18-4	2641-2644	the	abstract[142]|person[143]	new[142]|giv[143]	_	_
18-5	2645-2654	reviewers	abstract[142]|person[143]	new[142]|giv[143]	_	_
18-6	2655-2664	regarding	_	_	_	_
18-7	2665-2668	the	abstract[144]	new[144]	_	_
18-8	2669-2675	papers	abstract[144]	new[144]	_	_
18-9	2676-2679	and	_	_	_	_
18-10	2680-2684	data	abstract	giv	ana	18-13
18-11	2685-2694	extracted	_	_	_	_
18-12	2695-2699	from	_	_	_	_
18-13	2700-2704	them	abstract	giv	_	_
18-14	2705-2708	was	_	_	_	_
18-15	2709-2717	resolved	_	_	_	_
18-16	2718-2720	by	_	_	_	_
18-17	2721-2724	the	person[147]	new[147]	coref	22-24[183_147]
18-18	2725-2730	third	person[147]	new[147]	_	_
18-19	2731-2737	author	person[147]	new[147]	_	_
18-20	2738-2739	.	_	_	_	_

#Text=2.4 .
19-1	2740-2743	2.4	abstract	new	_	_
19-2	2744-2745	.	_	_	_	_

#Text=Assessment of Bias
20-1	2746-2756	Assessment	abstract[149]	new[149]	coref	21-52[170_149]
20-2	2757-2759	of	abstract[149]	new[149]	_	_
20-3	2760-2764	Bias	abstract[149]|abstract	new[149]|new	coref	21-6[153_0]

#Text=We assessed the risk of bias in each randomised and placebo-controlled study according to the Cochrane Review guidelines , which cover the following bias domains : Selection bias ( random sequence generation and allocation concealment ) , performance bias ( blinding of participants and personnel ) , detection bias ( blinding the outcome assessment ) , attrition bias ( incomplete outcome data ) , and reporting bias ( selective reporting ) .
21-1	2765-2767	We	person	giv	_	_
21-2	2768-2776	assessed	_	_	_	_
21-3	2777-2780	the	abstract[152]	new[152]	_	_
21-4	2781-2785	risk	abstract[152]	new[152]	_	_
21-5	2786-2788	of	abstract[152]	new[152]	_	_
21-6	2789-2793	bias	abstract[152]|abstract[153]	new[152]|giv[153]	coref	21-24[0_153]
21-7	2794-2796	in	abstract[152]|abstract[153]	new[152]|giv[153]	_	_
21-8	2797-2801	each	abstract[152]|abstract[153]|abstract[154]	new[152]|giv[153]|giv[154]	_	_
21-9	2802-2812	randomised	abstract[152]|abstract[153]|abstract[154]	new[152]|giv[153]|giv[154]	_	_
21-10	2813-2816	and	abstract[152]|abstract[153]|abstract[154]	new[152]|giv[153]|giv[154]	_	_
21-11	2817-2835	placebo-controlled	abstract[152]|abstract[153]|abstract[154]	new[152]|giv[153]|giv[154]	_	_
21-12	2836-2841	study	abstract[152]|abstract[153]|abstract[154]	new[152]|giv[153]|giv[154]	_	_
21-13	2842-2851	according	_	_	_	_
21-14	2852-2854	to	_	_	_	_
21-15	2855-2858	the	abstract[157]	giv[157]	_	_
21-16	2859-2867	Cochrane	place|abstract[156]|abstract[157]	giv|new[156]|giv[157]	_	_
21-17	2868-2874	Review	abstract[156]|abstract[157]	new[156]|giv[157]	_	_
21-18	2875-2885	guidelines	abstract[157]	giv[157]	_	_
21-19	2886-2887	,	_	_	_	_
21-20	2888-2893	which	_	_	_	_
21-21	2894-2899	cover	_	_	_	_
21-22	2900-2903	the	abstract[159]	new[159]	appos	21-27[161_159]
21-23	2904-2913	following	abstract[159]	new[159]	_	_
21-24	2914-2918	bias	abstract|abstract[159]	giv|new[159]	coref	21-48[168_0]
21-25	2919-2926	domains	abstract[159]	new[159]	_	_
21-26	2927-2928	:	_	_	_	_
21-27	2929-2938	Selection	abstract|abstract[161]	new|giv[161]	_	_
21-28	2939-2943	bias	abstract[161]	giv[161]	_	_
21-29	2944-2945	(	abstract[161]	giv[161]	_	_
21-30	2946-2952	random	abstract[161]	giv[161]	_	_
21-31	2953-2961	sequence	abstract[161]|abstract	giv[161]|new	_	_
21-32	2962-2972	generation	abstract[161]	giv[161]	_	_
21-33	2973-2976	and	abstract[161]	giv[161]	_	_
21-34	2977-2987	allocation	abstract[161]|abstract	giv[161]|new	_	_
21-35	2988-2999	concealment	abstract[161]	giv[161]	_	_
21-36	3000-3001	)	abstract[161]	giv[161]	_	_
21-37	3002-3003	,	abstract[161]	giv[161]	_	_
21-38	3004-3015	performance	abstract[161]|abstract	giv[161]|giv	_	_
21-39	3016-3020	bias	abstract[161]	giv[161]	_	_
21-40	3021-3022	(	abstract[161]	giv[161]	_	_
21-41	3023-3031	blinding	abstract[161]	giv[161]	_	_
21-42	3032-3034	of	_	_	_	_
21-43	3035-3047	participants	person[165]	giv[165]	_	_
21-44	3048-3051	and	person[165]	giv[165]	_	_
21-45	3052-3061	personnel	person[165]|person	giv[165]|new	_	_
21-46	3062-3063	)	_	_	_	_
21-47	3064-3065	,	_	_	_	_
21-48	3066-3075	detection	abstract|abstract[168]	new|giv[168]	coref|coref	21-57[172_168]|21-57[172_168]
21-49	3076-3080	bias	abstract[168]	giv[168]	_	_
21-50	3081-3082	(	_	_	_	_
21-51	3083-3091	blinding	_	_	_	_
21-52	3092-3095	the	abstract[170]	giv[170]	_	_
21-53	3096-3103	outcome	abstract|abstract[170]	new|giv[170]	coref	21-61
21-54	3104-3114	assessment	abstract[170]	giv[170]	_	_
21-55	3115-3116	)	_	_	_	_
21-56	3117-3118	,	_	_	_	_
21-57	3119-3128	attrition	event|abstract[172]	new|giv[172]	appos|appos	21-60[174_172]|21-60[174_172]
21-58	3129-3133	bias	abstract[172]	giv[172]	_	_
21-59	3134-3135	(	_	_	_	_
21-60	3136-3146	incomplete	abstract[174]	giv[174]	coref	21-66[175_174]
21-61	3147-3154	outcome	abstract|abstract[174]	giv|giv[174]	_	_
21-62	3155-3159	data	abstract[174]	giv[174]	_	_
21-63	3160-3161	)	_	_	_	_
21-64	3162-3163	,	_	_	_	_
21-65	3164-3167	and	_	_	_	_
21-66	3168-3177	reporting	abstract[175]	giv[175]	appos	21-69[176_175]
21-67	3178-3182	bias	abstract[175]	giv[175]	_	_
21-68	3183-3184	(	_	_	_	_
21-69	3185-3194	selective	abstract[176]	giv[176]	_	_
21-70	3195-3204	reporting	abstract[176]	giv[176]	_	_
21-71	3205-3206	)	_	_	_	_
21-72	3207-3208	.	_	_	_	_

#Text=The judgments were made independently by two researchers ( FM - M – A and R-F-V ) , with any discrepancies resolved with the third author ( OC ) .
22-1	3209-3212	The	abstract[177]	new[177]	_	_
22-2	3213-3222	judgments	abstract[177]	new[177]	_	_
22-3	3223-3227	were	_	_	_	_
22-4	3228-3232	made	_	_	_	_
22-5	3233-3246	independently	_	_	_	_
22-6	3247-3249	by	_	_	_	_
22-7	3250-3253	two	person[178]	new[178]	appos	22-10[179_178]
22-8	3254-3265	researchers	person[178]	new[178]	_	_
22-9	3266-3267	(	_	_	_	_
22-10	3268-3270	FM	person[179]	giv[179]	_	_
22-11	3271-3272	-	person[179]	giv[179]	_	_
22-12	3273-3274	M	person[179]|abstract	giv[179]|new	_	_
22-13	3275-3276	–	person[179]	giv[179]	_	_
22-14	3277-3278	A	person[179]|person[181]	giv[179]|new[181]	_	_
22-15	3279-3282	and	person[179]|person[181]	giv[179]|new[181]	_	_
22-16	3283-3288	R-F-V	person[179]|person[181]	giv[179]|new[181]	_	_
22-17	3289-3290	)	_	_	_	_
22-18	3291-3292	,	_	_	_	_
22-19	3293-3297	with	_	_	_	_
22-20	3298-3301	any	abstract[182]	new[182]	_	_
22-21	3302-3315	discrepancies	abstract[182]	new[182]	_	_
22-22	3316-3324	resolved	_	_	_	_
22-23	3325-3329	with	_	_	_	_
22-24	3330-3333	the	person[183]	giv[183]	appos	22-28[0_183]
22-25	3334-3339	third	person[183]	giv[183]	_	_
22-26	3340-3346	author	person[183]	giv[183]	_	_
22-27	3347-3348	(	_	_	_	_
22-28	3349-3351	OC	person	giv	_	_
22-29	3352-3353	)	_	_	_	_
22-30	3354-3355	.	_	_	_	_
